NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
February 28, 2024 17:00 ET | atai Life Sciences
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
Dyadic Logo Current.jpg
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Madrigal logo.jpg
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
February 28, 2024 07:01 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal logo.jpg
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024 07:00 ET | Madrigal Pharmaceuticals, Inc.
Announced appointment of Mardi C. Dier as Chief Financial OfficerAnticipates resmetirom to become the first medicine approved for NASH; PDUFA date March 14, 2024Reports year-end 2023 cash, cash...
Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape
Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning
February 28, 2024 01:32 ET | Novotech
Novotech has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape.
New logo with tagline.jpg
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024 16:01 ET | Vaxcyte, Inc.
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult...
Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
February 27, 2024 10:00 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin...
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024 01:00 ET | Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
BrandCraft logo.jpg
Tanke Biosciences Corp Appoints Kenneth Marks to the Board of Directors
February 26, 2024 11:20 ET | BrandCraft
Las Vegas, Nevada, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tanke Biosciences Corp (OTC: TNBI) d.b.a BrandCraft Holdings, LLC today announced that Kenneth Marks has joined the board of directors.  Mr....
Jason Matuszewski, CEO of BioStem Technologies
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market
February 26, 2024 10:39 ET | PRISM MarketView
PRISM MarketView Highlights BioStem Technologies as it Targets Significant Opportunity in Wound Care Markets